Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 May;64(5):1659–1665. doi: 10.1128/iai.64.5.1659-1665.1996

A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge.

A I Fattom 1, J Sarwar 1, A Ortiz 1, R Naso 1
PMCID: PMC173976  PMID: 8613375

Abstract

The efficacy of capsular polysaccharide (CP)-specific antibodies elicited by active immunization with vaccines composed of Staphylococcus aureus types 5 and 8 CP linked to Pseudomonas aeruginosa exoprotein A or with immune immunoglobulin G (I-IgG) obtained from vaccinated plasma donors was tested in lethal and sublethal bacterial mouse challenge models. A dose of 2 x 10(5) CFU of S. aureus type 5 CP per mouse administered intraperitoneally (i.p.) with 5% hog mucin was found to cause 80 to 100% mortality in BALB/c mice within 2 to 5 days. Mice passively immunized i.p. 24 h earlier or subcutaneously 48 h earlier with 0.5 ml of I-IgG showed significantly higher average survival rates than animals receiving standard IgG or saline (P < 0.01) following the bacterial challenge. Animals actively immunized with the monovalent type 5 CP-P. aeruginosa exoprotein A conjugate showed a survival rate of 73% compared with 13% in phosphate-buffered saline-immunized animals. The prechallenge geometric mean titer of type 5 CP antibodies in animals that died was significantly (P < 0.05) lower than that of animals which survived the challenge (95.7 versus 223.6 micrograms/ml, respectively). The IgG was further evaluated in mice challenged i.p. with a sublethal dose of 5 x 10(4) CFU per mouse. Serial blood counts were performed on surviving animals at 6, 12, 24, and 48 h. Surviving animals were sacrificed at 72 h, and bacterial counts were performed on their kidneys, livers, and peritoneal lavage fluids. Animals receiving I-IgG had lower bacterial counts in blood samples and lower bacterial densities in kidneys, livers, and peritoneal lavage samples than mice immunized with standard IgG (P < 0.05). These data suggest that S. aureus type 5 CP antibodies induced by active immunization or administered by passive immunization confer protection against S. aureus infections.

Full Text

The Full Text of this article is available as a PDF (301.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albus A., Arbeit R. D., Lee J. C. Virulence of Staphylococcus aureus mutants altered in type 5 capsule production. Infect Immun. 1991 Mar;59(3):1008–1014. doi: 10.1128/iai.59.3.1008-1014.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Albus A., Fournier J. M., Wolz C., Boutonnier A., Ranke M., Høiby N., Hochkeppel H., Döring G. Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis. J Clin Microbiol. 1988 Dec;26(12):2505–2509. doi: 10.1128/jcm.26.12.2505-2509.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Arbeit R. D., Dunn R. M. Expression of capsular polysaccharide during experimental focal infection with Staphylococcus aureus. J Infect Dis. 1987 Dec;156(6):947–952. doi: 10.1093/infdis/156.6.947. [DOI] [PubMed] [Google Scholar]
  4. Arbeit R. D., Karakawa W. W., Vann W. F., Robbins J. B. Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis. 1984 Apr;2(2):85–91. doi: 10.1016/0732-8893(84)90002-6. [DOI] [PubMed] [Google Scholar]
  5. Arbeit R. D., Nelles M. J. Capsular polysaccharide antigenemia in rats with experimental endocarditis due to Staphylococcus aureus. J Infect Dis. 1987 Feb;155(2):242–246. doi: 10.1093/infdis/155.2.242. [DOI] [PubMed] [Google Scholar]
  6. Baddour L. M., Lowrance C., Albus A., Lowrance J. H., Anderson S. K., Lee J. C. Staphylococcus aureus microcapsule expression attenuates bacterial virulence in a rat model of experimental endocarditis. J Infect Dis. 1992 Apr;165(4):749–753. doi: 10.1093/infdis/165.4.749. [DOI] [PubMed] [Google Scholar]
  7. Boutonnier A., Nato F., Bouvet A., Lebrun L., Audurier A., Mazie J. C., Fournier J. M. Direct testing of blood culture for detection of the serotype 5 and 8 capsular polysaccharides of Staphylococcus aureus. J Clin Microbiol. 1989 May;27(5):989–993. doi: 10.1128/jcm.27.5.989-993.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bryant R. E., Sanford J. P., Alcoze T. Treatment of recurrent furunculosis with staphylococcal bacteriophage-lysed vaccine. JAMA. 1965 Oct 4;194(1):11–14. [PubMed] [Google Scholar]
  9. DILLENBERG H. Experiences with a polyvalent staphylococcal vaccine with alpha-toxoid. Can J Public Health. 1962 Jun;53:248–253. [PubMed] [Google Scholar]
  10. DILLENBERG H., WALDRON M. P. A PREVENTIVE APPROACH TO IMPETIGO OF TREATY INDIANS USING STAPHYLOCOCCUS POLYVALENT SOMATIC ANTIGEN VACCINE. Can Med Assoc J. 1963 Nov 2;89:947–949. [PMC free article] [PubMed] [Google Scholar]
  11. Dassy B., Stringfellow W. T., Lieb M., Fournier J. M. Production of type 5 capsular polysaccharide by Staphylococcus aureus grown in a semi-synthetic medium. J Gen Microbiol. 1991 May;137(5):1155–1162. doi: 10.1099/00221287-137-5-1155. [DOI] [PubMed] [Google Scholar]
  12. Daum R. S., Fattom A., Freese S., Karakawa W. Capsular polysaccharide serotypes of coagulase-positive staphylococci associated with tenosynovitis, osteomyelitis, and other invasive infections in chickens and turkeys: evidence for new capsular types. Avian Dis. 1994 Oct-Dec;38(4):762–771. [PubMed] [Google Scholar]
  13. Ekstedt R. D. Immune response to surface antigens of Staphylococcus aureus and their role in resistance to staphylococcal disease. Ann N Y Acad Sci. 1974 Jul 31;236(0):203–220. doi: 10.1111/j.1749-6632.1974.tb41492.x. [DOI] [PubMed] [Google Scholar]
  14. FISHER M. W., DEVLIN H. B., ERLANDSON A. L. A NEW STAPHYLOCOCCAL ANTIGEN. ITS PREPARATION AND IMMUNIZING ACTIVITY AGAINST EXPERIMENTAL INFECTIONS. Nature. 1963 Sep 14;199:1074–1075. doi: 10.1038/1991074a0. [DOI] [PubMed] [Google Scholar]
  15. FISHER S. Observations on an antistaphylococcal mouse protective antibody in human sera. Aust J Exp Biol Med Sci. 1961 Oct;39:413–421. doi: 10.1038/icb.1961.42. [DOI] [PubMed] [Google Scholar]
  16. Fattom A., Schneerson R., Szu S. C., Vann W. F., Shiloach J., Karakawa W. W., Robbins J. B. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun. 1990 Jul;58(7):2367–2374. doi: 10.1128/iai.58.7.2367-2374.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fattom A., Schneerson R., Watson D. C., Karakawa W. W., Fitzgerald D., Pastan I., Li X., Shiloach J., Bryla D. A., Robbins J. B. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun. 1993 Mar;61(3):1023–1032. doi: 10.1128/iai.61.3.1023-1032.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Fattom A., Shiloach J., Bryla D., Fitzgerald D., Pastan I., Karakawa W. W., Robbins J. B., Schneerson R. Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionate. Infect Immun. 1992 Feb;60(2):584–589. doi: 10.1128/iai.60.2.584-589.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Foster T. J. Potential for vaccination against infections caused by Staphylococcus aureus. Vaccine. 1991 Apr;9(4):221–227. doi: 10.1016/0264-410x(91)90103-d. [DOI] [PubMed] [Google Scholar]
  20. Fournier J. M., Hannon K., Moreau M., Karakawa W. W., Vann W. F. Isolation of type 5 capsular polysaccharide from Staphylococcus aureus. Ann Inst Pasteur Microbiol. 1987 Sep-Oct;138(5):561–567. doi: 10.1016/0769-2609(87)90041-x. [DOI] [PubMed] [Google Scholar]
  21. Fournier J. M., Vann W. F., Karakawa W. W. Purification and characterization of Staphylococcus aureus type 8 capsular polysaccharide. Infect Immun. 1984 Jul;45(1):87–93. doi: 10.1128/iai.45.1.87-93.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. GREENBERG L., COOPER M. Y. Polyvalent somatic antigen for the prevention of staphylococcal infection. Can Med Assoc J. 1960 Jul 23;83:143–147. [PMC free article] [PubMed] [Google Scholar]
  23. GREENBERG L., LE RICHE W. H. Staphylococcal enzyme lysed soluble vaccine. Can J Public Health. 1961 Nov;52:479–485. [PubMed] [Google Scholar]
  24. Greenberg D. P., Ward J. I., Bayer A. S. Influence of Staphylococcus aureus antibody on experimental endocarditis in rabbits. Infect Immun. 1987 Dec;55(12):3030–3034. doi: 10.1128/iai.55.12.3030-3034.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Heidelberger M., Macpherson C. F. QUANTITATIVE MICRO-ESTIMATION OF ANTIBODIES IN THE SERA OF MAN AND OTHER ANIMALS. Science. 1943 Apr 30;97(2522):405–406. doi: 10.1126/science.97.2522.405. [DOI] [PubMed] [Google Scholar]
  26. Hochkeppel H. K., Braun D. G., Vischer W., Imm A., Sutter S., Staeubli U., Guggenheim R., Kaplan E. L., Boutonnier A., Fournier J. M. Serotyping and electron microscopy studies of Staphylococcus aureus clinical isolates with monoclonal antibodies to capsular polysaccharide types 5 and 8. J Clin Microbiol. 1987 Mar;25(3):526–530. doi: 10.1128/jcm.25.3.526-530.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. KOENIG M. G. Factors relating to the virulence of staphylococci. I. Comparative studies on two colonial variants. Yale J Biol Med. 1962 Jun;34:537–559. [PMC free article] [PubMed] [Google Scholar]
  28. Karakawa W. W., Fournier J. M., Vann W. F., Arbeit R., Schneerson R. S., Robbins J. B. Method for the serological typing of the capsular polysaccharides of Staphylococcus aureus. J Clin Microbiol. 1985 Sep;22(3):445–447. doi: 10.1128/jcm.22.3.445-447.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Karakawa W. W., Sutton A., Schneerson R., Karpas A., Vann W. F. Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun. 1988 May;56(5):1090–1095. doi: 10.1128/iai.56.5.1090-1095.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Koenig M. G., Melly M. A. The importance of surface antigens in staphylococcal virulence. Ann N Y Acad Sci. 1965 Jul 23;128(1):231–250. doi: 10.1111/j.1749-6632.1965.tb11641.x. [DOI] [PubMed] [Google Scholar]
  31. Lee J. C., Betley M. J., Hopkins C. A., Perez N. E., Pier G. B. Virulence studies, in mice, of transposon-induced mutants of Staphylococcus aureus differing in capsule size. J Infect Dis. 1987 Nov;156(5):741–750. doi: 10.1093/infdis/156.5.741. [DOI] [PubMed] [Google Scholar]
  32. Lee J. C., Perez N. E., Hopkins C. A., Pier G. B. Purified capsular polysaccharide-induced immunity to Staphylococcus aureus infection. J Infect Dis. 1988 Apr;157(4):723–730. doi: 10.1093/infdis/157.4.723. [DOI] [PubMed] [Google Scholar]
  33. Lee J. C., Takeda S., Livolsi P. J., Paoletti L. C. Effects of in vitro and in vivo growth conditions on expression of type 8 capsular polysaccharide by Staphylococcus aureus. Infect Immun. 1993 May;61(5):1853–1858. doi: 10.1128/iai.61.5.1853-1858.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Melly M. A., Duke L. J., Liau D. F., Hash J. H. Biological properties of the encapsulated Staphylococcus aureus M. Infect Immun. 1974 Aug;10(2):389–397. doi: 10.1128/iai.10.2.389-397.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Melly M. A., McGee Z. A., Horn R. G., Morris F., Glick A. D. An electron microscopic India ink technique for demonstrating capsules on microorganisms: studies with Streptococcus pneumoniae, Staphylococcus aureus, and Neisseria gonorrhoeae. J Infect Dis. 1979 Oct;140(4):605–609. doi: 10.1093/infdis/140.4.605. [DOI] [PubMed] [Google Scholar]
  36. Moreau M., Richards J. C., Fournier J. M., Byrd R. A., Karakawa W. W., Vann W. F. Structure of the type 5 capsular polysaccharide of Staphylococcus aureus. Carbohydr Res. 1990 Jul 1;201(2):285–297. doi: 10.1016/0008-6215(90)84244-o. [DOI] [PubMed] [Google Scholar]
  37. Nemeth J., Lee J. C. Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis. Infect Immun. 1995 Feb;63(2):375–380. doi: 10.1128/iai.63.2.375-380.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Peterson P. K., Wilkinson B. J., Kim Y., Schmeling D., Quie P. G. Influence of encapsulation on staphylococcal opsonization and phagocytosis by human polymorphonuclear leukocytes. Infect Immun. 1978 Mar;19(3):943–949. doi: 10.1128/iai.19.3.943-949.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Poutrel B., Boutonnier A., Sutra L., Fournier J. M. Prevalence of capsular polysaccharide types 5 and 8 among Staphylococcus aureus isolates from cow, goat, and ewe milk. J Clin Microbiol. 1988 Jan;26(1):38–40. doi: 10.1128/jcm.26.1.38-40.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Poutrel B., Gilbert F. B., Lebrun M. Effects of culture conditions on production of type 5 capsular polysaccharide by human and bovine Staphylococcus aureus strains. Clin Diagn Lab Immunol. 1995 Mar;2(2):166–171. doi: 10.1128/cdli.2.2.166-171.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Poutrel B., Sutra L. Type 5 and 8 capsular polysaccharides are expressed by Staphylococcus aureus isolates from rabbits, poultry, pigs, and horses. J Clin Microbiol. 1993 Feb;31(2):467–469. doi: 10.1128/jcm.31.2.467-469.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Quie P. G. Bactericidal function of human polymorphonuclear leukocytes. E. Mead Johnson Award Address. Pediatrics. 1972 Aug;50(2):264–270. [PubMed] [Google Scholar]
  43. Robbins J. B., Schneerson R. Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis. 1990 May;161(5):821–832. doi: 10.1093/infdis/161.5.821. [DOI] [PubMed] [Google Scholar]
  44. Rogers D. E., Melly M. A. Speculations on the immunology of staphylococcal infections. Ann N Y Acad Sci. 1965 Jul 23;128(1):274–284. doi: 10.1111/j.1749-6632.1965.tb11644.x. [DOI] [PubMed] [Google Scholar]
  45. SALMON G. G., Jr, SYMONDS M. STAPHAGE LYSATE THERAPY IN CHRONIC STAPHYLOCOCCAL INFECTIONS. J Med Soc N J. 1963 May;60:188–193. [PubMed] [Google Scholar]
  46. Schneerson R., Barrera O., Sutton A., Robbins J. B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med. 1980 Aug 1;152(2):361–376. doi: 10.1084/jem.152.2.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Stringfellow W. T., Dassy B., Lieb M., Fournier J. M. Staphylococcus aureus growth and type 5 capsular polysaccharide production in synthetic media. Appl Environ Microbiol. 1991 Feb;57(2):618–621. doi: 10.1128/aem.57.2.618-621.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Sutra L., Mendolia C., Rainard P., Poutrel B. Encapsulation of Staphylococcus aureus isolates from mastitic milk: relationship between capsular polysaccharide types 5 and 8 and colony morphology in serum-soft agar, clumping factor, teichoic acid, and protein A. J Clin Microbiol. 1990 Mar;28(3):447–451. doi: 10.1128/jcm.28.3.447-451.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Sutra L., Rainard P., Poutrel B. Phagocytosis of mastitis isolates of Staphylococcus aureus and expression of type 5 capsular polysaccharide are influenced by growth in the presence of milk. J Clin Microbiol. 1990 Oct;28(10):2253–2258. doi: 10.1128/jcm.28.10.2253-2258.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Sutton A., Vann W. F., Karpas A. B., Stein K. E., Schneerson R. An avidin-biotin based ELISA for quantitation of antibody to bacterial polysaccharides. J Immunol Methods. 1985 Oct 10;82(2):215–224. doi: 10.1016/0022-1759(85)90353-9. [DOI] [PubMed] [Google Scholar]
  51. Xu S., Arbeit R. D., Lee J. C. Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun. 1992 Apr;60(4):1358–1362. doi: 10.1128/iai.60.4.1358-1362.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Yoshida K., Ichiman Y., Narikawa S., Evans W. B. Staphylococcal capsular vaccine for preventing mastitis in two herds in Georgia. J Dairy Sci. 1984 Mar;67(3):620–627. doi: 10.3168/jds.S0022-0302(84)81347-8. [DOI] [PubMed] [Google Scholar]
  53. Yoshida K., Ichiman Y., Narikawa S., Takahashi M., Kono E., San Clemente C. L. Passive protection by human serum in mice infected with encapsulated Staphylococcus aureus. J Med Microbiol. 1979 Aug;12(3):277–282. doi: 10.1099/00222615-12-3-277. [DOI] [PubMed] [Google Scholar]
  54. Zollinger W. D., Boslego J. W. A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies. J Immunol Methods. 1981;46(2):129–140. doi: 10.1016/0022-1759(81)90130-7. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES